India’s weight loss category is undergoing a dynamic transformation triggered by scientific improvements, pharma innovation, ...

The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment ...

The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment ...

Novo Nordisk and the Chinese group’s wholly-owned subsidiary The United Bio-Technology have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, ...

According to Monday’s news release, the candidate, OPK-88006, is set to be the first oral GLP-1/glucagon agonist to start human studies. Under the terms of the agreement, OPKO and Entera will split ...

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.

Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures," said Kevin McCulloch, President and COO of Xeris. "American Regent is the ...

NEW YORK--(BUSINESS WIRE)--Nussbaum Law Group, P.C. and Roberts Law Firm US, PC: A proposed settlement (“Settlement”) has been reached in a class action lawsuit alleging that Mylan N.V., Mylan ...

This leaflet answers some common questions about RABEPRAZOLE MYLAN. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.